PrimeRFP SCOUT · Federal Contract Recompete Brief

75N91020F00026 — DEVELOPMENT OF TARGET CHARACTERIZATION METHODS FOR NOVEL CANCER MARKERS

DEVELOPMENT OF TARGET CHARACTERIZATION METHODS FOR NOVEL CANCER MARKERS is a federal award for Department of Health and Human Services (HHS) held by LEIDOS BIOMEDICAL RESEARCH, INC.. Estimated value $56.5M ($15.5M obligated). Current period of performance ends May 25, 2027.

$56.5M
Estimated Value
$15.5M
Obligated
May 25, 2027
PoP End / Expires

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

LEIDOS BIOMEDICAL RESEARCH, INC. holds $2.3B across 187 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 4 related awards under parent 75N91019D00024. Recompete timing centers on the May 25, 2027 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

Federal
Contract number75N91020F00026
AgencyDepartment of Health and Human Services (HHS)
IncumbentLEIDOS BIOMEDICAL RESEARCH, INC.
UEIHV8BH9BPG8Y9
NAICS541715
PSCAN12
Parent IDIQ / IDV75N91019D00024
PoP end (current)May 25, 2027
Obligated$15.5M

DEVELOPMENT OF TARGET CHARACTERIZATION METHODS FOR NOVEL CANCER MARKERS

Recompete timing

Public
Expiring in 282 days

Current PoP ends May 25, 2027 (282 days remaining). Agencies typically plan 12–18 months ahead — at 9.3 months out, that window is already open. The buying decision is likely already in motion.

Watch this contract — one email →

Incumbent footprint

Public record

LEIDOS BIOMEDICAL RESEARCH, INC.$2.3B obligated across 187 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$2.3B · 100% of firm total
Open full company profile

Related awards

Same parent · incumbent
75N91020F00025
DCR IS REQUESTING THE SERVICES OF LEIDOS BIOMEDICAL RESEARCH, INC. TO INITIATE MANAGEMENT,…
$97.5M
Sep 24, 2028
75N91019F00139
MD NET
$163.5M
Sep 29, 2028
75N91020F00039
NIAID COVID-19 ACTIV3
$281.6M
Sep 29, 2029
75N91021F00004
ADVANCE UNIVERSAL INFLUENZA VACCINE - FLU MOSAIC VERSION 2 (FLUMOSV2)
$141.7M
Jan 28, 2031

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See the recompete window for 75N91020F00026
More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open LEIDOS BIOMEDICAL RESEARCH, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75N91020F00026?

75N91020F00026 (DEVELOPMENT OF TARGET CHARACTERIZATION METHODS FOR NOVEL CANCER MARKERS) is a Department of Health and Human Services (HHS) award with an estimated value of $56.5M, currently held by LEIDOS BIOMEDICAL RESEARCH, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75N91020F00026?

LEIDOS BIOMEDICAL RESEARCH, INC. is the incumbent with $2.3B across 187 related awards in SCOUT’s public footprint. The current period of performance ends May 25, 2027.

When does 75N91020F00026 come up for recompete?

SCOUT tracks a period-of-performance end of May 25, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75N91019D00024-75N91020F00026